Cava is a phenomenal business, but Dutch Bros is no slouch. Today, Dutch Bros is the better buy. If Cava's valuation sinks to a more reasonable level, investors would be wise to jump on it. Until then ...
With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but that are still worth investing in: CRISPR Therapeutics (NASDAQ: CRSP) and ...